The sBCMA level has been suggested as a biomarker since it is significantly higher in MM patients compared to healthy individuals, and higher levels are associated with poor prognosis [37,38], MM progression, and poor response to BCMA-targeted therapy [38,39]. This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.